| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/26/2001 | CN1328136A Polypeptide-DNA topoisomerase II-beta (TOP2B) 29.48 and polynucleotide for coding it |
| 12/26/2001 | CN1328061A Application of genetically engineered fish growth hormone in aquatic product culture |
| 12/26/2001 | CN1328060A Polypeptide-human oxysteroid bindin 38.72 and polynucleotide for coding it |
| 12/26/2001 | CN1328059A Polypeptide-human cell cyclin G29.13 and polynucleotide for coding it |
| 12/26/2001 | CN1328057A Polypeptide-human FK506 bindin 12.32 and polynucleotide for coding it |
| 12/26/2001 | CN1328055A Polypeptide-insulin-like growth factor bindin 16.17 and polynucleotide for coding it |
| 12/26/2001 | CN1328043A Polypeptide-human periplastic dynein intermediate chain (IC) 9.35 and polynucleotide for coding it |
| 12/26/2001 | CN1328040A Polypeptide-human zinc finger protein 18.04 and polynucleotide for coding it |
| 12/26/2001 | CN1328032A Polypeptide-human mitochondrion translation initiation factor 8.8 and polynucleotide for coding it |
| 12/26/2001 | CN1328024A Polypeptide-human Na-K pump 14.85 and polynucleotide for coding it |
| 12/26/2001 | CN1328017A Polypeptide-human TNFR/NGFR protein 12 containing cytochrome C structure domain and polynucleotide for coding it |
| 12/26/2001 | CN1328011A Polypeptide-gamma-carboxylglutamate protein 113.31 richly contained in proline and polynucleotide for coding it |
| 12/26/2001 | CN1328009A Polypeptide-Ras GTP enzyme activated protein 12 and polynucleotide for coding it |
| 12/26/2001 | CN1328000A Polypeptide-glycosyl-phosphatidyl inositol polyose F11.22 and polynucleotide for coding it |
| 12/26/2001 | CN1327998A Polypeptide-nuclein matrix antigen 115.29 and polynucleotide for coding it |
| 12/26/2001 | CN1327993A Polypeptide-estrogen receptor associated protein 19.03 and polynucleotide for coding it |
| 12/26/2001 | CN1327991A Polypeptide-complement receptor 12 and polynucleotide for coding it |
| 12/26/2001 | CN1327854A Composite lysostaphin enzyme spray for oral cavity and its preparing process |
| 12/26/2001 | CN1327853A Stable alpha-interferon preparation |
| 12/26/2001 | CN1076624C Nasally administrable compositions |
| 12/25/2001 | US6333447 Transgenic model of heart failure |
| 12/25/2001 | US6333408 Oligonucleotides inhibitors of PAI-1 MRNA |
| 12/25/2001 | US6333403 Nucleotide sequences coding polypeptide associated with tumors; for use in diagnosis and treatment of tumors |
| 12/25/2001 | US6333402 For therapy and diagnosis |
| 12/25/2001 | US6333400 Amino acid transporters and sues |
| 12/25/2001 | US6333395 Exhibit anti-membrane fusion capability, antiviral activity, such as the ability to inhibit hiv transmission to uninfected cells |
| 12/25/2001 | US6333359 Regulation of cellular apoptosis using modulators of β-AR receptors |
| 12/25/2001 | US6333350 Use of nitric oxide donors and/or substrates or nitric oxide inhibitors for regulating cervical dilatation and extensibility |
| 12/25/2001 | US6333348 Use of docetaxel for treating cancers |
| 12/25/2001 | US6333321 For therapy of unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, thrombotic stroke, embolic stroke, disseminated intravascular coagulation, deep venous thrombosis, pulmonary embolism, and reocclusion |
| 12/25/2001 | US6333318 Used in therapy; for delivering recombinant proteins into a variety of cells within a patient |
| 12/25/2001 | US6333314 Radiosensitizing tumor tissue by administration of formulation comprising cationic liposome, phosphatidylcholine and cholesterol, and encapsulated antisense oligonucleotide |
| 12/25/2001 | US6333313 Formulating an oxytocin receptor stimulator into a pharmaceutically acceptable formulation; administering an amount of said oxytocin receptor stimulator effective to maintain or increase bone formation and/or inhibit bone |
| 12/25/2001 | US6333312 Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases |
| 12/25/2001 | US6333311 Has inflammatory and immune response functions such as regulation of monocyte colony stimulating factor synthesis, regulation of interleukin synthesis, activation of natural killer cell activity, inhibition of metastasis |
| 12/25/2001 | US6333310 NGF variants |
| 12/25/2001 | US6333309 Having anti-tumor activity, a leukemia cell differentiation inducing activity, a cellular immunology enhancing activity, a vascular endothelial cell growth stimulating activity and a hepatocyte growth stimulating activity |
| 12/25/2001 | US6333308 Cyclic peptide derivatives |
| 12/25/2001 | US6333307 Compounds and method for modulating neurite outgrowth |
| 12/25/2001 | US6333306 Pharmaceutical combination preparations containing erythropoietin and iron preparations |
| 12/25/2001 | US6333305 For therapy of fungal infections |
| 12/25/2001 | US6333304 For therapy of arthroses in animals |
| 12/25/2001 | US6333303 Antiviral ricin-like proteins |
| 12/25/2001 | US6333174 Transforming a bacterial inoculant with a replicable plasmid having a double stranded dna, a tryptophan promoter, ribosome binding site, a translation start signal with structural genes coding a leade, culture with tryptophan |
| 12/25/2001 | US6333172 An expression system for expressing a nucleic acid encoding polypeptide for 3-hydroxy-3-methylglutaryl coa (hmg coa) reductase degradation (hrd) protein; for assay to screen and regulate cholesterol biosynthesis |
| 12/25/2001 | US6333168 Cloning, expression and uses of dorsalin-1 |
| 12/25/2001 | US6333161 Assaying a test ligands ability to bind a central nervous system receptor by incubation the ligand with mutant cells that produce a kainate-binding excitatory amino acid receptor and determining the extent of binding |
| 12/25/2001 | US6333153 Modifying duplex dna by mixing the mismatch duplex dna with a muts homolog dimer in the presence of a binding solution which contains adenosine triphosphate nucleotides at a concentration of less than 3 micromolar |
| 12/25/2001 | US6333057 Composition and method for topical treatment of androgenic alopecia |
| 12/25/2001 | US6333051 Nanogel networks and biological agent compositions thereof |
| 12/25/2001 | US6333041 Nontoxic vernix compositions and method of producing |
| 12/25/2001 | US6333037 Methods for treating pain with a modified neurotoxin |
| 12/25/2001 | US6333034 Administering anti-properdin agent effective to selectively inhibit formation of an alternative complement pathway activation product |
| 12/25/2001 | US6333032 Administering to antibody to gamma interferon in an amount effective to neutralize or reduce fluid activity levels of gamma interferon for therapy of multiple sclerosis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis |
| 12/25/2001 | US6333021 For delivery of therapeutically and/or diagnostically active substance, when in suspension in physiologically acceptable carrier useful as delivery vehicles for therapeutically active agents and/or as contrast agents for echographic imaging |
| 12/25/2001 | CA2184582C Pharmaceutically acceptable dnase formulation |
| 12/25/2001 | CA2172779C Cgrp antagonist used for the treatment of pruritus and ocular or palpebral dysesthesia |
| 12/25/2001 | CA2139385C Products containing g-csf and tnf binding protein |
| 12/25/2001 | CA2099497C Peptides with anticoagulant activity |
| 12/25/2001 | CA2094027C Osteogenic peptides |
| 12/25/2001 | CA2066728C Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists |
| 12/25/2001 | CA2018714C Hypothalamic polypeptides with adenylate cyclase stimulating activity |
| 12/23/2001 | CA2312109A1 Use of furin and furin-like protease inhibitors in the treatment of inflammatory or matrix remodelling diseases |
| 12/20/2001 | WO2001096879A2 Method and apparatus for monitoring anti-platelet agents |
| 12/20/2001 | WO2001096873A2 Method for identifying apoptosis-modified proteins |
| 12/20/2001 | WO2001096598A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF |
| 12/20/2001 | WO2001096586A1 Antisense modulation of c/ebp alpha expression |
| 12/20/2001 | WO2001096576A1 A novel polypeptide, a human atp-dependent serine protein hydrolase 10 and the polynucleotide encoding the polypeptide |
| 12/20/2001 | WO2001096574A1 Novel enzyme gene and its expression product |
| 12/20/2001 | WO2001096572A1 A novel polypeptide- multi-copper oxidase 12 and the polynucleotide encoding said polypeptide |
| 12/20/2001 | WO2001096565A2 Binding agents: chimeric ligand/receptor proteins |
| 12/20/2001 | WO2001096564A2 Hla-g (hla-g7) isoform and its applications |
| 12/20/2001 | WO2001096563A1 Scramblase 2 |
| 12/20/2001 | WO2001096561A1 Hunc-2, human member of unc-protein family |
| 12/20/2001 | WO2001096559A2 Regulatable, catalytically active nucleic acids |
| 12/20/2001 | WO2001096558A1 Polyfunctional base sequence and artificial gene containing the same |
| 12/20/2001 | WO2001096553A1 Novel g protein-coupled receptor protein and dna thereof |
| 12/20/2001 | WO2001096550A1 Novel mouse cia protein and cia gene having anti-apoptotic activity as a selective inhibitor of cad interacting ask1 and use thereof |
| 12/20/2001 | WO2001096548A2 Human n-acetyltransferase family member and uses thereof |
| 12/20/2001 | WO2001096547A2 Human kinases |
| 12/20/2001 | WO2001096546A2 Protein phosphatases |
| 12/20/2001 | WO2001096542A2 A human aminotransferase (23680) and uses thereof |
| 12/20/2001 | WO2001096538A2 Regulation of human transmembrane serine protease |
| 12/20/2001 | WO2001096535A2 Nucleic acid coding for a bonding site of a protein kinase of the mitogenic signalling cascade of a glycolysis-catalysing enzyme |
| 12/20/2001 | WO2001096534A1 A novel polypeptide, a atp-dependant human rna helicase 11 and the polynucleotide encoding the polypeptide |
| 12/20/2001 | WO2001096527A2 Peptides with physiological activity |
| 12/20/2001 | WO2001096526A2 A novel polypeptide, a human tumor suppressor factor 11.77 and the polynucleotide encoding the polypeptide |
| 12/20/2001 | WO2001096524A2 A novel polypeptide, a human sigma receptor 10.67 and the polynucleotide encoding the polypeptide |
| 12/20/2001 | WO2001096399A2 Novel interferon-induced tetraspan protein and nucleic acids encoding same |
| 12/20/2001 | WO2001096397A2 Cd154 variants and uses thereof |
| 12/20/2001 | WO2001096395A2 Biosynthetic oncolytic molecules and uses therefor |
| 12/20/2001 | WO2001096394A2 Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders |
| 12/20/2001 | WO2001096393A2 Nucleotide and amino acid sequences of oocyte factors for altering ovarian follicular growth in vivo or in vitro |
| 12/20/2001 | WO2001096391A2 55p4h4: gene expressed in various cancers |
| 12/20/2001 | WO2001096390A2 Compositions and methods for the therapy and diagnosis of colon cancer |
| 12/20/2001 | WO2001096388A2 Compositions and methods for the therapy and diagnosis of colon cancer |
| 12/20/2001 | WO2001096385A1 Codon optimised recombinant dermaphagoides allergens |
| 12/20/2001 | WO2001096379A2 Immunization of dairy cattle with chimeric gapc protein against streptococcus infection |
| 12/20/2001 | WO2001096378A2 Human epithin-like serine protease |
| 12/20/2001 | WO2001096376A2 Pro-apoptotic fragments of the dengue virus envelope glycoproteins |